Iterum Therapeutics Files Proxy Materials

TL;DR

Iterum Therapeutics filed proxy docs, no fee. Standard corporate stuff.

AI Summary

Iterum Therapeutics plc filed a Definitive Additional Materials proxy statement on September 23, 2024. This filing is related to the company's proxy statement and does not involve a fee, as indicated by the 'No fee required' checkbox. The filing is made under Schedule 14A, which pertains to proxy solicitations.

Why It Matters

This filing indicates that Iterum Therapeutics is proceeding with shareholder communications and potential corporate actions requiring proxy approval, which is a standard part of corporate governance.

Risk Assessment

Risk Level: low — This is a routine administrative filing related to proxy statements and does not contain new financial information or strategic decisions that would inherently increase risk.

Key Players & Entities

• Iterum Therapeutics plc (company) — Registrant
• 0000950170-24-108613.txt (document) — Filing document identifier
• 20240923 (date) — Filing date

FAQ

Filing Documents

• itrm-20240923.htm (DEFA14A) — 39KB
• 0000950170-24-108613.txt ( ) — 40KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Iterum Therapeutics plc (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 ITERUM THERAPEUTICS PLC SUPPLEMENT TO NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS AND DEFINITIVE PROXY STATEMENT FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ORIGINALLY SCHEDULED TO BE HELD ON MONDAY, SEPTEMBER 9, 2024 Iterum Therapeutics plc (the “Company”) intends to adjourn, without conducting any business, its extraordinary general meeting of shareholders (EGM), currently scheduled to take place on Monday, September 23, 2024, at 1.30 p.m. Irish time (8.30 a.m., U.S. Eastern Time) to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (SEC) on August 14, 2024 (the Proxy Statement). The EGM will reconvene on Monday, September 30, 2024, beginning at 1.30 p.m. Irish time (8.30 a.m., U.S. Eastern Time) at 3 Dublin Landings, North Wall Quay, Dublin 1, Ireland. The record date for the EGM continues to be the close of business on August 9, 2024. Shareholders who have previously submitted their proxy or otherwise voted on the proposals at the EGM and who do not want to change their vote need not take any action. You may change your vote and revoke your proxy prior to the EGM by doing any one of the following things: • submitting a new proxy by following the “Online” or “Phone” instructions on the enclosed proxy card at a date later than your previous vote but prior to the voting deadline (which is 4.59 a.m., Irish time on September 30, 2024 (11.59 p.m., Eastern Time on September 29, 2024)); or • signing another proxy card and either arranging for delivery of that proxy card by mail to our registered office prior to the start of the EGM, or by delivering that signed proxy card in person at the EGM; or • giving our Secretary a written notice before or at the EGM that you want to revoke your proxy; or • voting in person at the EGM. For questions relating to the voting of shares or to request additional or misplaced proxy voting materials, please contact the company secretary by email, in writing or by telephone as follows: legal@iterumtx.com , c/o Secretary, Iterum Therapeutics plc, Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, Ireland, Phone: +353 1 6694820. As described in the Proxy Statement, a shareholder on the record date may use one of the following methods to vote before the reconvening of the adjourned EGM on September 30, 2024: (1) You may vote over the Internet. You may vote your shares by following the Online instructions on your proxy card. If you vote over the Internet, you do not need to vote by telephone or complete and mail your proxy card. The internet voting facilities for eligible shareholders of record will close at 4.59 a.m., Irish time on September 30, 2024 (11.59 p.m., Eastern Time on September 29, 2024). (2) You may vote by telephone. You may vote your shares by following the Phone instructions on your proxy card. If you vote by telephone, you do not need to vote over the Internet or complete and mail your proxy card. If you vote by telephone, your use of that telephone system, and specifically the entry of your pin number/other unique identifier, will be deemed to constitute your appointment, in writing and under hand, and for all purposes of the Irish Companies Act 2014, of each of David G. Kelly, Louise Barrett and Kevin Dalton as your proxy to vote your shares on your behalf in accordance with your telephone instructions. The telephone voting facilities for eligible shareholders of record will close at 4.59 a.m., Irish time on September 30, 2024 (11.59 p.m., Eastern Time on September 29, 2024). (3) You may vote by mail. You may vote by completing, dating and signing the proxy card provided to you and promptly mailing it in the provided postage-paid envelope. If you vote by mail, you do not need to vote over the Internet or by telephone. The Company must receive the completed proxy card by 5.00 p.m., Irish t

View Full Filing

View this DEFA14A filing on SEC EDGAR